Motif Bio Investors - MTFB

Motif Bio Investors - MTFB

Best deals to access real time data!
Level 2 Basic
Monthly Subscription
for only
Monthly Subscription
for only
UK/US Silver
Monthly Subscription
for only
VAT not included
Stock Name Stock Symbol Market Stock Type Stock ISIN Stock Description
Motif Bio Plc MTFB London Ordinary Share GB00BVVT4H71 ORD 0.01P
  Price Change Price Change % Stock Price Last Trade
0.00 0.0% 0.50 01:00:00
Open Price Low Price High Price Close Price Previous Close
more quote information »
Industry Sector

Top Investor Posts

scottdavid70: Pains me to have to spell it out again to investors but I have been waiting for someone with a modicum of intelligence to point the blatantly obvious out from the last RNS - but no luck. So I will do it. Where it says ‘marketingR17; will begin in the second half of April read ‘attempt to get funding’ (no mention of the need for marketing in the RNS end of January) New audit rules y/e Dec 2020 read “total red herring” Where it says Aim admission document read will be published end of April early May read “completely dependent on funding” absolutely nothing to do with the the sham audit reason. Simple but some on here still don’t understand what is going on - you will eventually get it If you don’t believe email the company and ask if the funding is in place as the AIM admission document was supposed to be out end of March so it should have been and no marketing needed. You won’t get a reply trust me and then the penny will drop. Lummy and Goldy still lining their pockets whilst keeping ‘some’ investors in the dark Happy Easter
scottdavid70: Kind of crazy what investors will take. More than likely the take home pay with zero risk for Gold and Lumsden will be 25% plus of the value of the ENTIRE NEW COMPANY VALUATION on RTO if investors vote it through. Personally I won’t accept these crumbs along with what has happened with Iclaprim and Orange Avenue Technologies LLC. It’s grotesque greed for me and a message needs to be sent that investors have a strong voice
scottdavid70: I often wonder what Mr Lumsden feels when he puts his head on a pillow at night after telling investors on the 19th February 2019 that no clinical trials were indicated by the FDA in their webcast post the CRL decision. I believe a full phase iii trial constitutes new clinical trials. He has since then run from investors and pocketed a million plus in salary as well as other Directors who made this a gravy train despite failing to get Iclaprim approved. There are many aspects of these dismal Directors abilities to look after shareholders interests to dissect but the actions post the 14th February 2019 are the most pertinent when looking at both men’s characters. That’s why I believe there is so much more to the Orange Avenue Technologies LLC story than currently we as shareholders are being told
scottdavid70: It’s absolutely stunning that investors here aren’t incredulous at the Orange Avenue Technologies LLC situation. Who honestly believes that John Palmer a turnaround specialist suddenly has the intellectual property acumen to sell a antibiotic all on his own? Clearly there are others helping him. So who are they and why can’t we find out ANYTHING AT ALL about the new company??? Even at the end the Lumsden fingerprint of failure is all over this for investors
scottdavid70: Bet Palmer worked hard to seek Iclaprim when he knew these clowns would present him with this opportunity. Probably been smoking a fat cigar waiting for the clock to run down. Turnaround specialist- don’t be fooled - just another part of the greedy conglomerate who have shown zero empathy for the hard working ordinary investors What value do you think long term suffering Motif investors will get in the new company for Iclaprim over the new mob? My thoughts are a pittance bit of course Palmer now handsomely profits, Good hugely profits through his deferred salary that has now had 2 EXTRA months of pay due to them being late completing the RTO and Lumsden with his LAUGHABLE BONUS The greed machine gears keep on grinding
scottdavid70: Chatting to many investors we are pretty sure that the deal won’t be structured in a way that gives any meaningful value back to the long term investors. No sense that this BoD has put our interests over theirs when you look at the salaries they have paid themselves despite failing. Genuinely believe they don’t realise how many shares individual investors held by the end of July 2020 to vote down any RTO that just shoves more wads of cash into their pockets. I will wait for the finer details which of course will come once Gold has secured his last deferred salary payment in March but currently the mood is to vote against it
scottdavid70: As I have said there are only two possible reasons to run it this close: 1) That there is a imminent sale of Iclaprim that could provide upside to investors and that there were actually several companies wanting to do a deal with Motif and that it was so competitive it has taken this long to strike the right deal. If true, this would potentially create enormous value for shareholders whom came late top the party. Those invested on Lumsdens promises at +/- 30p are still going to be massively disappointed. Had they known liver experts had been on standby would probably have pulled their cash before Feb 14th. 2) Option 2 this is run. so close as to make investors feel that anything is better than nothing even if they get diluted to 10% of their current holding. Option 2 is my go to given what investors have had to deal with and see from this Board for 2 years now. I dont think it will delist and even if it does it maybe better than option 2 as we might still be able to get some upside from Iclaprim due to the contractual arrangement. RTO into a minnow we may lose that given how this Board has diluted and negotiated for us up to now
scottdavid70: Seasons Greeting and Happy Christmas to those that celebrate it to all the hard working ordinary investors here and there are many who have financed Graham Lumsden, Jon Gold, Bruce Williams and Chris Wardhaugh presents or celebrations. The same goes to Peel Hunt and Walbrook who have trousered so much of the investors monies to play their staff and in term allowed them to enjoy their Christmas indirectly benefitting from investors by making the Boards words seem believable. To the ordinary hard working people here I hope you can enjoy it and be safe in the knowledge that this will be the last Christmas you have to endure as a shareholder in this company. There will be no salvation here for investors and I hope in the long run not for the Board either for their reputations
scottdavid70: So Motif got several offers to do a RTO due to companies wanting to get their COViD therapeutics to market. Motif then hire Peel Hunt who have failed over and over gain to realise value for investors despite making huge sums for themselves. Walbrook whom take hundred of thousands of pounds to not reply to investors. Were Peel Hunt brought in as they knew the skeletons? Why use the same company that has failed investors before with their predictions? Makes no sense? Why do Walbrook refuse to answer questions? Does anyone else smell a Graham here?
scottdavid70: For example, how are investors not emailing Motif and Walbrook to ask about the new patents this August for Iclaprim and Sandoz every day? Your investment could depend on what that means but they won’t mention it even happened. Yet they agree there is a contract in place that investors could benefit from via a sale so therefore it stands to reason that the investors here who have been shafted by the Board to date should be informed of the potential upside these patents mean
ADVFN Advertorial
Your Recent History
Motif Bio
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210415 11:39:37